Cardio Diagnostics Holdings (CDIO) Interest Expenses (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Interest Expenses of $65610.0 for Q1 2026, up 2762.57% sequentially from $2292.0 in Q4 2025, and up 1.21% YoY from $64827.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Interest Expenses (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Interest Expenses for 6 years, with the latest figure at $65610.0 in Q1 2026.
- Quarterly Interest Expenses rose 1.21% year-over-year to $65610.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135856.0 (up 102.09% YoY) and the FY2025 annual result came in at $260612.0, down 95.35% from the prior year.
- Interest Expenses rose to $65610.0 in Q1 2026 per CDIO's latest filing, from $2292.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $5.0 million in Q1 2023 and troughed at -$6.6 million in Q4 2023.
- A 5-year average of $209122.1 and a median of $83835.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses tumbled 113628.22% in 2023, then soared 100.05% in 2024.
- Over 5 years, Interest Expenses stood at $5829.0 in 2022, then sank by 113628.22% to -$6.6 million in 2023, then soared by 100.05% to $3127.0 in 2024, then dropped by 26.7% to $2292.0 in 2025, then soared by 2762.57% to $65610.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $65610.0, $2292.0, and $102060.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | 3,440.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314,547.00 |
| Jun 30, 2026 | 314,547.00 |
| Mar 31, 2026 | 65,610.00 |
| Mar 31, 2026 | 65,610.00 |
| Dec 31, 2025 | 2,292.00 |
| Dec 31, 2025 | 2,292.00 |
| Sep 30, 2025 | 102,060.00 |
| Sep 30, 2025 | 102,060.00 |
| Jun 30, 2025 | 576,725.00 |
| Jun 30, 2025 | 576,725.00 |
| Mar 31, 2025 | 64,827.00 |
| Mar 31, 2025 | 64,827.00 |
| Dec 31, 2024 | 3,127.00 |
| Dec 31, 2024 | 3,127.00 |
| Sep 30, 2024 | 771,205.00 |
| Sep 30, 2024 | 771,205.00 |
| Jun 30, 2024 | 835,774.00 |
| Jun 30, 2024 | 835,774.00 |
| Mar 31, 2024 | 64,056.00 |
| Mar 31, 2024 | 64,056.00 |